Cirtuvivint is under clinical development by Biosplice Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cirtuvivint’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cirtuvivint overview

SM-08502 is under development for the treatment of castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), endometrial cancer, or ovarian cancer, acute myelocytic leukemia, pancreatic cancer and B-cell chronic lymphocytic leukemia. The therapeutic candidate is formulated as tablet and administered through oral route. The drug candidate acts by targeting CDC-like kinase 2 (CLK2) and CDC-like kinase 3 (CLK3).

Biosplice Therapeutics overview

Biosplice Therapeutics is a biotechnology company that develops CLK/DYRK kinase based small-molecule drugs for musculoskeletal diseases, inflammation, and oncology disorders. It is investigating Cirtuvivint (SM08502) inhibitor to treat metastatic castration-resistant prostate cancer, heme malignancies, and solid tumors; lorecivivint (SM04690) against hip, shoulder and knee osteoarthritis and degenerative disc diseases. Biosplice Therapeutics is also evaluating DYRK1A (dual specificity tyrosine-phosphorylation-regulated kinase 1A), an oral brain penetrant for the treatment of Alzheimer’s disease, traumatic brain injury and select therapies. The company’s scientific platform is based on biological discoveries that govern tissue specialization. Biosplice Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of Cirtuvivint’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.